Standard BioTools Inc
NASDAQ:LAB
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
1.42
2.92
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one LAB stock under the Base Case scenario is 1.09 USD. Compared to the current market price of 1.71 USD, Standard BioTools Inc is Overvalued by 36%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Standard BioTools Inc
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for LAB cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Economic Moat
Standard BioTools Inc
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Standard BioTools Inc
Balance Sheet Decomposition
Standard BioTools Inc
Current Assets | 480m |
Cash & Short-Term Investments | 394.7m |
Receivables | 32.4m |
Other Current Assets | 52.9m |
Non-Current Assets | 228.7m |
PP&E | 74.1m |
Intangibles | 130.3m |
Other Non-Current Assets | 24.3m |
Current Liabilities | 123.8m |
Accounts Payable | 12.6m |
Accrued Liabilities | 37.8m |
Other Current Liabilities | 73.5m |
Non-Current Liabilities | 74.7m |
Long-Term Debt | 299k |
Other Non-Current Liabilities | 74.4m |
Earnings Waterfall
Standard BioTools Inc
Revenue
|
136.3m
USD
|
Cost of Revenue
|
-72.7m
USD
|
Gross Profit
|
63.6m
USD
|
Operating Expenses
|
-176.7m
USD
|
Operating Income
|
-113.1m
USD
|
Other Expenses
|
-51.5m
USD
|
Net Income
|
-164.7m
USD
|
Free Cash Flow Analysis
Standard BioTools Inc
USD | |
Free Cash Flow | USD |
LAB Profitability Score
Profitability Due Diligence
Standard BioTools Inc's profitability score is 24/100. The higher the profitability score, the more profitable the company is.
Score
Standard BioTools Inc's profitability score is 24/100. The higher the profitability score, the more profitable the company is.
LAB Solvency Score
Solvency Due Diligence
Standard BioTools Inc's solvency score is 73/100. The higher the solvency score, the more solvent the company is.
Score
Standard BioTools Inc's solvency score is 73/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
LAB Price Targets Summary
Standard BioTools Inc
According to Wall Street analysts, the average 1-year price target for LAB is 3.14 USD with a low forecast of 2.53 USD and a high forecast of 4.2 USD.
Dividends
Current shareholder yield for LAB is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Fluidigm Corp. is engaged in the development, manufacture, and marketing of biotechnology tools for life sciences research. The company is headquartered in South San Francisco, California and currently employs 615 full-time employees. The company went IPO on 2011-02-10. The firm operates in development, manufacturing, and commercialization of tools for life sciences research. Its technology, mass cytometry is a multiplexed solution to analyze cell-surface and intracellular proteins simultaneously in cell suspensions including blood and disassociated tissues. Its Imaging Mass Cytometry (IMC) technology allows multiplexed imaging to understand the composition of tissue microenvironments at a subcellular 1-micron resolution. The company markets technologies and life science tools, including preparatory and analytical instruments for mass cytometry, library prep, single cell genomics, and consumables, including integrated fluidic circuits. Its analytical instruments include Biomark HD System, EP1 System, and Hyperion Tissue Imager.
Contact
IPO
Employees
Officers
The intrinsic value of one LAB stock under the Base Case scenario is 1.09 USD.
Compared to the current market price of 1.71 USD, Standard BioTools Inc is Overvalued by 36%.